report_details_header_image

US Insulin Market Research Report and Forecast 2023-2028

“US Insulin Market Research Report and Forecast 2023-2028” provides a deep and thorough evaluation of the insulin market in the United States on the basis of drug class (Fast-acting insulin, Intermediate-acting insulin and Long-acting insulin), application (Type 1 diabetes and Type 2 diabetes) and insulin delivery technologies (Injectable insulin, Oral insulin, Inhaled insulin, Other emerging Insulin Delivery Technologies and Insulin pumps). Insulin refers to a medication used as a substitute for insulin hormone produced by pancreas to control blood sugar levels. Irregularities in hormone levels can lead to abnormally high or low blood sugar that causes serious health problems. Premixed, rapid, short, intermediate, and long-acting are some commonly used variants of insulin prescribed by physicians. It can be administered using various devices, such as syringes, pens, pumps, jet injections, and inhalers. Insulin is widely used to treat and control metabolic syndrome and various diabetes, such as gestational, type 1, type 2, and prediabetes. It also aids in regulating the body’s metabolism of carbohydrates, fats, and proteins.

The increasing prevalence of diabetes due to the rising incidences of obesity and sedentary lifestyles are among the key factors driving the US insulin market growth. In addition to this, increasing consumer awareness regarding various product benefits, such as high efficacy, minimal adverse effects, enhanced convenience, and lower weight gain, is acting as another growth-inducing factor. Furthermore, various initiatives by the Federal Government of the United States (US Federal Government), such as the inflation reduction act that places a monthly cap on insulin prices, which, in turn, provides relief to beneficiaries and reduces out-of-pocket expenses for patients, are positively influencing the market growth. Additionally, the integration of recombinant deoxyribonucleic acid (DNA) technology to produce safe and cost-effective insulin with a longer shelf-life and reduced risk of allergies and immune rejection is providing an impetus to the market growth. Moreover, the recent development of the automated insulin delivery (AID) system that reduces the mental burden of micromanaging glucose levels and aids in efficient diabetes management is favoring the market growth. Other factors, including the rising geriatric population, increasing investments in research and development (R&D) of new drugs, and escalating awareness among the masses regarding efficient diabetes care, are anticipated to drive the market growth.   

Beginning with a regional overview, the report explores the dynamics that have a strong influence on the US insulin market and also impact its future growth. Taking 2022 as the base year, the report covers historical market scenario from 2017-2022 and provides forecasts till 2028. This includes the study of value and volume trends as well as pricing history. Growth inducing factors, market restraints and recent developments have also been analyzed in the report in order to provide deeper knowledge about the industry.

The report analyses the competitive structure of the US insulin industry and provides the profiles of major players operating in the market. The price margins for the products, along with the various success and risk factors for manufacturers, have also been covered in the report. Moreover, in order to determine market attractiveness, the report analyses the US insulin industry along the parameters of Porter’s Five Forces model. This model examines the degree of competition in the US insulin industry by analysing the threat posed by new entrants and substitutes and the bargaining power of suppliers and buyers. SWOT analysis of the market has also been presented in the report, which highlights the strengths, weaknesses, opportunities and threats pertaining to the US insulin industry. Furthermore, the value chain analysis of the US insulin industry has also been covered in the report. This comprises all the activities in the value chain, such as the procurement of various raw materials, manufacturing, sales and distribution.

US Insulin Market Key Segments

Segmentation by Drug Class

  • Fast-Acting Insulin
  • Intermediate-Acting Insulin
  • Long-Acting Insulin

Segmentation by Application

  • Type 1 diabetes
  • Type 2 diabetes

Segmentation by Insulin Delivery Technologies

  • Injectable Insulin
  • Oral Insulin
  • Inhaled Insulin
  • Other Emerging Insulin Delivery Technologies
  • Insulin Pumps

The price margins for the products along with various success and risk factors for manufacturers have also been covered in the report. Moreover, in order to determine market attractiveness, the report analyses the US insulin industry along the parameters of the Porter’s Five Forces model. This model examines the degree of competition in the US insulin market by analyzing the threats posed by new entrants and substitutes, and the bargaining power of suppliers and buyers. SWOT analysis of the market has also been presented in the report which highlights the strengths, weaknesses, opportunities and threats pertaining to the insulin industry. Furthermore, the value chain analysis of the insulin industry has also been covered in the report. This comprises of all the activities in the value chain, such as the procurement of various raw materials, manufacturing and sales of the products, and their distribution.

Key questions answered in the report include

  • What is the historical and current scenario of the US insulin market?
  • What are the trends and developments in the US insulin market?
  • What is the market forecast of the US insulin market during 2023-2028?
  • What is the price analysis and forecast of the insulin market?
  • What is the Porter’s five forces analysis of the US insulin market?
  • What is the SWOT analysis for the US insulin market?
  • What is the value chain analysis of the US insulin market?

The report is a result of exhaustive primary and secondary research undertaken by analysts having years of experience in the insulin industry. All the qualitative and quantitative aspects of the industry have been covered and the collected data has been analyzed and presented in the form of easily comprehensible charts, graphs and tables.

Purchase Options

Customization

Access Tailored Insights Designed for Your Business.

Ask For Customization

Personalize this research

Triangulate with your own data

Get data as per your format and definition

Gain a deeper dive on a specific application, geography, customer or competitor

Any level of personalization

Get in Touch

Call us on

US: +1-213-316-7435

Uk: +44-20-8040-3201


Drop us an email at

sales@syndicatedanalytics.com

Related Reports